Ginsenoside Improve Metabolic Syndrome

Effects of Ginsenoside Supplementation on Insulin Resistance and Cardiometabolic Risk Factors in Men With Metabolic Syndrome: a Randomized Controlled Trial.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02034136

Enrollment

Registered

2014-01-13

Start date

2014-02-28

Completion date

2014-12-31

Last updated

2014-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Aim : Investigated the effects of Korean red ginseng supplementation on metabolic parameters such as cholesterol, blood pressure and glucose. Randomized Control Trial.

Detailed description

Methods : A randomized, double-blind, placebo-controlled, single-center study in 60 subjects who are not taking drugs that could affect metabolic and vascular function. Subjects will be randomized into a Korean red ginseng (3.0g/d) group or placebo group for a 4-week study. We will collect anthropometric measurements, blood for laboratory testing, inflammatory marker, hormones and mitochondrial DNA copy number. Subject : Older than 40 years of age, presented with metabolic syndrome. Subjects were excluded if they were taking drugs that could affect metabolic and vascular function, including BP control drug, anti-diabetic drugs and lipid-lowering drugs. Measurement : We will collect anthropometric measurements and blood for laboratory testing at the initial(week 0) and final (week 4)visits. Serum levels of blood glucose, insulin, total cholesterol, HDL-cholesterol,triglyceride, and DNA copy number of mitochondria.

Interventions

DIETARY_SUPPLEMENTDietary fiber fill

3g/day, 28days

DIETARY_SUPPLEMENTGinsenoside

3.0 g/ d for 28 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* metabolic syndrome

Exclusion criteria

* Taking drug for lipid-lowering, BP control and anti-diabetic.

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline in metabolic syndrome profile at week 4	Baseline and 4 weeks from intake of Ginsenoside	Total cholesterol, HDL-Cholesterol, Glucose, Blood Pressure, Body weight

Secondary

Measure	Time frame	Description
Change from baseline in hormones at week 4.	Initial and 4 weeks later	insulin ,cortisol, testosterone, somatomedin-c and DHEAS

Other

Measure	Time frame
Mitochondria DNA copy number	initial and 4 weeks later

Countries

South Korea

Contacts

Primary ContactDH Jung, MPH

balsan2@empas.com+82) 10-4204-8998

Backup ContactYJ Lee, Ph.D

ykyjhome@yuhs.ac+82) 3015-2011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026